SCHEMBL97675

SCHEMBL97675

OCc1sc(-c2ccccc2)nc1-c1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 10/20 0.68
KDM4E B2RXH2 4/20 0.68
POLB P06746 1/20 0.68
ALDH1A1 P00352 4/20 0.57
KMT2A Q03164 3/20 0.57
MAPT P10636 2/20 0.57
NPSR1 Q6W5P4 1/20 0.57
CYP1A2 P05177 1/20 0.57
CYP2C9 P11712 1/20 0.57
HPGD P15428 1/20 0.57
CYP2C19 P33261 1/20 0.57
AR P10275 1/20 0.52
MEN1 O00255 2/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
PPARG P37231 1/20 0.50
NCOA2 Q15596 1/20 0.50
NCOA1 Q15788 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
GALK1 P51570 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4463500 0.87 PTGDR2 (0.55) PTGDR2KDM4EPOLBALDH1A1KMT2A
SCHEMBL11466220 0.81 ALDH1A1 (0.67) PTGDR2KDM4EPOLBALDH1A1KMT2A
SCHEMBL97674 0.81 PTGDR2 (0.68) PTGDR2KDM4EPOLBALDH1A1KMT2A
SCHEMBL4497493 0.81 PTGDR2 (1.00) PTGDR2KDM4EPOLBALDH1A1KMT2A
SCHEMBL9093724 0.80 AR (0.51) PTGDR2KDM4EPOLBALDH1A1KMT2A
SCHEMBL3077683 0.80 SMN1; SMN2 (0.56) PTGDR2KDM4EPOLBALDH1A1MAPT
SCHEMBL5873074 0.78 KDM4E (0.58) PTGDR2KDM4EPOLBALDH1A1KMT2A
SCHEMBL3032002 0.76 PTGDR2 (0.56) PTGDR2KDM4EPOLBALDH1A1KMT2A
SCHEMBL11994177 0.76 ATP4A (0.58) PTGDR2KDM4EPOLBALDH1A1KMT2A
SCHEMBL978395 0.76 KMT2A (0.75) PTGDR2KDM4EPOLBALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB PTGDR2 1452/4885KDM4E 1125/4885POLB 1340/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 PTGDR2 335/4885KDM4E 3919/4885POLB 4329/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 PTGDR2 335/4885KDM4E 3919/4885POLB 4329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.